A probabilistic evaluation of the Dutch robustness and model-based selection protocols for Head-and-Neck IMPT: A multi-institutional study.

Head and Neck Model-based selection Polynomial Chaos Expansion Probabilistic planning Proton therapy Robust planning Robustness analysis Robustness evaluation

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 21 03 2024
revised: 12 07 2024
accepted: 15 07 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 28 7 2024
Statut: aheadofprint

Résumé

In the Netherlands, 2 protocols have been standardized for PT among the 3 proton centers: a robustness evaluation (RE) to ensure adequate CTV dose and a model-based selection (MBS) approach for IMPT patient-selection. This multi-institutional study investigates (i) inter-patient and inter-center variation of target dose from the RE protocol and (ii) the robustness of the MBS protocol against treatment errors for a cohort of head-and-neck cancer (HNC) patients treated in the 3 Dutch proton centers. Clinical treatment plans of 100 HNC patients were evaluated. Polynomial Chaos Expansion (PCE) was used to perform a comprehensive robustness evaluation per plan, enabling the probabilistic evaluation of 100,000 complete fractionated treatments. PCE allowed to derive scenario distributions of clinically relevant dosimetric parameters to assess CTV dose (D For the CTV The standardization of the RE and MBS protocol lead to comparable results in terms of TCP and the NTCPs. Still, significant inter-patient and inter-center variation in dosimetric parameters remained due to clinical practice differences at each institution. The MBS approach is a robust protocol to qualify patients for PT.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
In the Netherlands, 2 protocols have been standardized for PT among the 3 proton centers: a robustness evaluation (RE) to ensure adequate CTV dose and a model-based selection (MBS) approach for IMPT patient-selection. This multi-institutional study investigates (i) inter-patient and inter-center variation of target dose from the RE protocol and (ii) the robustness of the MBS protocol against treatment errors for a cohort of head-and-neck cancer (HNC) patients treated in the 3 Dutch proton centers.
MATERIALS AND METHODS METHODS
Clinical treatment plans of 100 HNC patients were evaluated. Polynomial Chaos Expansion (PCE) was used to perform a comprehensive robustness evaluation per plan, enabling the probabilistic evaluation of 100,000 complete fractionated treatments. PCE allowed to derive scenario distributions of clinically relevant dosimetric parameters to assess CTV dose (D
RESULTS RESULTS
For the CTV
CONCLUSION CONCLUSIONS
The standardization of the RE and MBS protocol lead to comparable results in terms of TCP and the NTCPs. Still, significant inter-patient and inter-center variation in dosimetric parameters remained due to clinical practice differences at each institution. The MBS approach is a robust protocol to qualify patients for PT.

Identifiants

pubmed: 39069084
pii: S0167-8140(24)00711-4
doi: 10.1016/j.radonc.2024.110441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110441

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jesús Rojo-Santiago (J)

Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, the Netherlands; HollandPTC, Delft, the Netherlands. Electronic address: j.rojosantiago@erasmusmc.nl.

Steven J M Habraken (SJM)

Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, the Netherlands; HollandPTC, Delft, the Netherlands.

Mirko Unipan (M)

GROW School for Oncology, Maastricht University Medical Center, Department of Radiation Oncology (Maastro), Maastricht, the Netherlands.

Stefan Both (S)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Geert Bosmans (G)

GROW School for Oncology, Maastricht University Medical Center, Department of Radiation Oncology (Maastro), Maastricht, the Netherlands.

Zoltán Perkó (Z)

Delft University of Technology, Department of Radiation Science and Technology, Delft, the Netherlands.

Erik Korevaar (E)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Mischa S Hoogeman (MS)

Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, the Netherlands; HollandPTC, Delft, the Netherlands.

Classifications MeSH